{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:47:09Z","timestamp":1762102029071},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Natural Science Foundation of the People\u2019s Republic of China","award":["81171886","81372587"],"award-info":[{"award-number":["81171886","81372587"]}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7132018"],"award-info":[{"award-number":["7132018"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing City Board of Education Development Project","award":["KZ201310025021"],"award-info":[{"award-number":["KZ201310025021"]}]},{"name":"Project of Construction of Innovative Teams and Teacher Career Development for Universities and Colleges under Beijing Municipality","award":["IDHT20140514"],"award-info":[{"award-number":["IDHT20140514"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.phrs.2017.04.026","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T06:02:46Z","timestamp":1493186566000},"page":"145-157","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson\u2019s disease on liver cancer"],"prefix":"10.1016","volume":"121","author":[{"given":"Shao-Song","family":"Xi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Xu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Hui","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2017.04.026_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.parkreldis.2009.11.005","article-title":"Cancer risk in association with Parkinson disease: a population-based study","volume":"16","author":"Becker","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.phrs.2017.04.026_bib0010","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.tins.2005.05.002","article-title":"To die or grow: Parkinson\u2019s disease and cancer","volume":"28","author":"West","year":"2005","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2017.04.026_bib0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjc.6602279","article-title":"Atypical cancer pattern in patients with Parkinson\u2019s disease","volume":"92","author":"Olsen","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2017.04.026_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40035-015-0043-z","article-title":"The associations between Parkinson\u2019s disease and cancer: the plot thickens","volume":"4","author":"Feng","year":"2015","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.phrs.2017.04.026_bib0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/aje\/kwt232","article-title":"Parkinson\u2019s disease and cancer: a register-based family study","volume":"179","author":"Wirdefeldt","year":"2014","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.phrs.2017.04.026_bib0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1146\/annurev.neuro.27.070203.144244","article-title":"Unraveling the mechanisms involved in motor neuron degeneration in ALS","volume":"27","author":"Bruijn","year":"2004","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2017.04.026_bib0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson\u2019s disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2017.04.026_bib0040","article-title":"Metabotropic glutamate receptors as therapeutic targets in Parkinson\u2019s disease: an update from the last 5 years of research","author":"Litim","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2017.04.026_bib0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00424-010-0809-1","article-title":"Glutamate receptors, neurotoxicity and neurodegeneration","volume":"460","author":"Lau","year":"2010","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.phrs.2017.04.026_bib0050","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neulet.2010.09.043","article-title":"Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson\u2019s disease","volume":"486","author":"Black","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2017.04.026_bib0055","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.brainres.2004.11.040","article-title":"Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP","volume":"1033","author":"Aguirre","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2017.04.026_bib0060","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1460-9568.2005.04362.x","article-title":"Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson\u2019s disease","volume":"22","author":"Vernon","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.phrs.2017.04.026_bib0065","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-06-3665","article-title":"Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma","volume":"67","author":"Namkoong","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2017.04.026_bib0070","first-page":"81","article-title":"Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma","volume":"17","author":"Park","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2017.04.026_bib0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2014.09.008","article-title":"Targeting putative mu opioid\/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model","volume":"743","author":"Smeester","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2017.04.026_bib0080","doi-asserted-by":"crossref","first-page":"6372","DOI":"10.1073\/pnas.091113598","article-title":"Glutamate antagonists limit tumor growth","volume":"98","author":"Rzeski","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.04.026_bib0085","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/nm0901-1010","article-title":"Glutamate release promotes growth of malignant gliomas","volume":"7","author":"Takano","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2017.04.026_bib0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jat.1413","article-title":"Selective blockade of mGlu5 metabotropic glutamate receptors is hepatoprotective against fulminant hepatic failure induced by lipopolysaccharide and D-galactosamine in mice","volume":"29","author":"Jesse","year":"2009","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.phrs.2017.04.026_bib0095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0168-8278(02)00384-7","article-title":"Selective blockade of mGlu5 metabotropic glutamate receptors is protective against acetaminophen hepatotoxicity in mice","volume":"38","author":"Storto","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2017.04.026_bib0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.510310315","article-title":"Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage","volume":"31","author":"Storto","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2017.04.026_bib0105","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.biochi.2012.06.006","article-title":"The suppressive effect of metabotropic glutamate receptor 5 (mGlu5) inhibition on hepatocarcinogenesis","volume":"94","author":"Wu","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.phrs.2017.04.026_bib0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jnr.10632","article-title":"Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK","volume":"73","author":"Ugarte","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.phrs.2017.04.026_bib0115","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00421-008-0849-9","article-title":"Anaerobic exercise reduces tumor growth, cancer cachexia and increases macrophage and lymphocyte response in Walker 256 tumor-bearing rats","volume":"104","author":"de Lima","year":"2008","journal-title":"Eur. J. Appl. Physiol."},{"key":"10.1016\/j.phrs.2017.04.026_bib0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/bdd.380","article-title":"Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine","volume":"25","author":"Levi","year":"2004","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.phrs.2017.04.026_bib0125","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.freeradbiomed.2015.09.017","article-title":"Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson's disease model","volume":"89","author":"Xia","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2017.04.026_bib0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/jnr.20198","article-title":"6-Hydroxydopamine induces dopaminergic cell degeneration via a caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression","volume":"77","author":"Liang","year":"2004","journal-title":"J Neurosci. Res."},{"key":"10.1016\/j.phrs.2017.04.026_bib0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ijc.23048","article-title":"Dulxanthone A induces cell cycle arrest and apoptosis via up-regulation of p53 through mitochondrial pathway in HepG2 cells","volume":"122","author":"Tian","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2017.04.026_bib0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2017.04.026_bib0145","article-title":"Metabotropic glutamate receptors in cancer","author":"Yu","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2017.04.026_bib0150","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"Akt\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2017.04.026_bib0155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.18632\/oncotarget.302","article-title":"Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy","volume":"7","author":"Sokolosky","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2017.04.026_bib0160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jbior.2013.09.013","article-title":"Diverse roles of GSK-3: tumor promoter-tumor suppressor: target in cancer therapy","volume":"54","author":"McCubrey","year":"2014","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.phrs.2017.04.026_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0306-4522(98)00189-4","article-title":"Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion","volume":"88","author":"Meshul","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2017.04.026_bib0170","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7150\/ijbs.6475","article-title":"Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications","volume":"9","author":"Willard","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.phrs.2017.04.026_bib0175","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nrc3150","article-title":"Parkinson\u2019s disease and cancer: two wars one front","volume":"11","author":"Devine","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2017.04.026_bib0180","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2017.04.026_bib0185","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson\u2019s disease","volume":"41","author":"Simon-Sanchez","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2017.04.026_bib0190","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jnen\/59.6.490","article-title":"Alpha-synuclein expression in central nervous system tumors showing neuronal or mixed neuronal\/glial differentiation","volume":"59","author":"Raghavan","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.phrs.2017.04.026_bib0195","doi-asserted-by":"crossref","first-page":"e10481","DOI":"10.1371\/journal.pone.0010481","article-title":"Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma","volume":"5","author":"Matsuo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2017.04.026_bib0200","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0197-4580(02)00196-3","article-title":"Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies","volume":"24","author":"Lee","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.phrs.2017.04.026_bib0205","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2017.04.026_bib0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/ng.491","article-title":"Somatic mutations of the Parkinson\u2019s disease-associated gene PARK2 in glioblastoma and other human malignancies","volume":"42","author":"Veeriah","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2017.04.026_bib0215","first-page":"6928","article-title":"Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS\/DJ-1 and RhoGDIalpha","volume":"63","author":"MacKeigan","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2017.04.026_bib0220","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/jcb.20159","article-title":"Differential control of apoptosis by DJ-1 in prostate benign and cancer cells","volume":"92","author":"Hod","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.phrs.2017.04.026_bib0225","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1073\/pnas.1012500108","article-title":"Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas","volume":"108","author":"Looyenga","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.04.026_bib0230","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/1440-1681.12410","article-title":"Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats","volume":"42","author":"Ferrigno","year":"2015","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.phrs.2017.04.026_bib0235","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbadis.2011.11.008","article-title":"Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson\u2019s disease: a self-perpetuating crosstalk?","volume":"1822","author":"Vairetti","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2017.04.026_bib0240","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.25898","article-title":"Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling","volume":"129","author":"Herner","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2017.04.026_bib0245","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1038\/npp.2014.85","article-title":"Stress hormone exposure reduces mGluR5 expression in the nucleus accumbens: functional implications for interoceptive sensitivity to alcohol","volume":"39","author":"Besheer","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2017.04.026_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-0082(00)00067-8","article-title":"Glutamate uptake","volume":"65","author":"Danbolt","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.phrs.2017.04.026_bib0255","doi-asserted-by":"crossref","first-page":"9463","DOI":"10.1158\/0008-5472.CAN-07-2034","article-title":"Autocrine glutamate signaling promotes glioma cell invasion","volume":"67","author":"Lyons","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2017.04.026_bib0260","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/pcmr.12207","article-title":"Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells","volume":"27","author":"Wall","year":"2014","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.phrs.2017.04.026_bib0265","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ejca.2011.01.017","article-title":"Des-g-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1\/2 MAPK signaling pathway","volume":"47","author":"Yue","year":"2011","journal-title":"Eur. J. Cancer"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816312907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816312907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T10:24:28Z","timestamp":1535883868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816312907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":53,"alternative-id":["S1043661816312907"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.04.026","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson\u2019s disease on liver cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}